January 15, 2024
Article
The initiation of immunotherapy at the end of life among patients with advanced cancers is increasing over time.
January 10, 2024
Article
The FDA has granted fast track designation to SLS009 for use in patients with relapsed or refractory acute myeloid leukemia.
January 09, 2024
Article
Camidanlumab tesirine was well tolerated as a monotherapy and elicited responses when given with pembrolizumab in patients with advanced solid tumors.
October 20, 2023
Article
Dostarlimab plus chemotherapy elicited a higher objective response rate and showcased a numerical improvement in overall survival compared with pembrolizumab and chemotherapy in patients with treatment-naïve, nonsquamous non–small cell lung cancer.